文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

挽救性近距离放疗治疗根治性放疗后局部复发前列腺癌:SFRO多中心法国队列

Salvage brachytherapy for locally recurrent prostate cancer after definitive radiotherapy - a multicentric French cohort by the SFRO brachytherapy group.
PubMed 文献 · Radiother Oncol · 2025-09-30

该多中心回顾性队列纳入2006至2022年法国7家中心266例根治性放疗后孤立性前列腺局部复发并接受挽救性近距离放疗的患者。中位随访60.1个月,50.7%出现生化复发,中位生化无进展生存40.0个月;初始高危、HDR技术及局灶治疗与bPFS显著相关,晚期3级胃肠和泌尿生殖毒性分别为3%和14%。

要点

  • 挽救性近距离放疗后中位bPFS为40.0个月,50.7%患者出现生化复发。
  • 初始高危、HDR技术及局灶治疗与更差bPFS独立相关。
  • 晚期3级胃肠毒性和泌尿生殖毒性发生率分别为3%和14%。

核心结论

  • 挽救性近距离放疗可获得令人鼓舞的疾病控制,毒性谱可接受,但仔细的患者选择仍然至关重要。

研究设计与样本

  • 法国SFRO近距离放疗组开展的多中心回顾性队列,纳入2006至2022年7家法国专家中心所有根治性放疗后孤立性前列腺局部复发并接受挽救性前列腺近距离放疗的患者,共266例。

主要发现

  • 中位随访60.1个月,135例(50.7%)出现生化复发,中位生化无进展生存期(bPFS)为40.0个月。
  • 多因素分析显示初始风险组高危(HR=1.64,95%CI[1.13-2.37],p=0.008)、BT技术为HDR(HR=2.14,95%CI[1.41-3.26],p=0.0004)及治疗体积为局灶对比全腺体(HR=2.14,95%CI[1.23-3.73],p=0.007)与bPFS显著相关。
  • 晚期3级胃肠道毒性和泌尿生殖毒性分别发生于3%和14%的患者。
  • 初诊时42%患者为高危疾病;主要放疗为外照射(EBRT)者占78%,其中3D适形技术最常见(51%),中位剂量74 Gy;复发时中位PSA为3.7 ng/mL。

临床怎么用

  • 对根治性放疗后孤立性前列腺局部复发患者,可考虑挽救性近距离放疗,但需严格选择患者。
  • 选择HDR技术或局灶治疗时需注意其与更差bPFS的独立关联,应结合患者情况权衡。
  • 需关注晚期泌尿生殖毒性(3级14%)和胃肠毒性(3级3%),做好随访监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Salvage brachytherapy (BT) after definitive irradiation for prostate cancer is gaining increasing interest, although many areas of uncertainty remain. MATERIALS AND METHODS: We established a large national retrospective cohort including all patients treated with salvage prostate BT for isolated prostatic local relapse after definitive radiotherapy between 2006 and 2022 in seven French expert centers. RESULTS: A total of 266 patients were included. At initial diagnosis, 42 % of patients presented with high-risk disease. Primary irradiation consisted of external beam radiotherapy (EBRT) in 78 % of cases, most commonly delivered with a 3D conformal technique (51 %), with a median dose of 74 Gy. Median PSA at relapse was 3.7 ng/mL. Salvage BT was performed using low-dose-rate (LDR) permanent iodine seed implantation in 63 % of patients and high-dose-rate (HDR) brachytherapy in 37 %. Seventy percent of patients were treated with whole-gland irradiation, while the remainder received a focal approach. In 34.5 % of cases, androgen deprivation therapy (ADT) was combined with salvage BT. After a median follow-up of 60.1 months, 135 (50.7 %) of patients experienced biochemical relapse. Median biochemical progression-free survival (bPFS) was 40.0 months. On multivariate analysis, initial risk group (high-risk: HR = 1.64, 95 % CI [1.13-2.37], p = 0.008), BT technique (HDR: HR = 2.14, 95 % CI [1.41-3.26], p = 0.0004), and treated volume (focal vs. whole-gland: HR = 2.14, 95 % CI [1.23-3.73], p = 0.007) were significantly associated with bPFS. Late grade 3 gastrointestinal and genitourinary toxicities occurred in 3 % and 14 % of patients, respectively. CONCLUSION: Salvage BT provides encouraging disease control with an acceptable toxicity profile. Careful patient selection remains essential.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kissel M, Ka K, Meraouna Y, et al. Salvage brachytherapy for locally recurrent prostate cancer after definitive radiotherapy - a multicentric French cohort by the SFRO brachytherapy group. Radiother Oncol. 2025. PMID: 41038281. doi:10.1016/j.radonc.2025.111170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。